转移性肾细胞癌患者护理管理

Nursing Care Management of Metastatic Renal Cell Cancer Patients

目的探讨苹果酸法米替尼首次用于转移性肾细胞癌患者的观察及护理。方法 2011年10月至2015年6月,泌尿外科接受新药苹果酸法米替尼治疗转移性肾细胞癌患者9例,通过随访过程中患者的不良反应发生情况及发生时间,研究护士给予相应的护理干预。结果白细胞降低、血小板降低、蛋白尿、手足综合征、贫血、高血压、食欲减退、腹泻、血尿、水肿和口腔黏膜炎发生率分别为88.9%、88.9%、88.9%、77.8%、66.7%、66.7%、66.7%、55.6%、33.3%、22.2%和22.2%,通过对症处理和护理干预,不良反应均处于可控范围内。结论苹果酸法米替尼治疗转移性肾细胞癌不良反应发生率较高,用药过程中严密观察和监测患者用药后的不良反应并及时护理,不仅保证用药的安全性,更使患者获得最大受益。

Objective To investigate the adverse events in metastatic renal cell cancer patients during ad- ministration of famitinib malate and the significance of related nursing care. Methods All nine metastatic renal cell cancer patients were prescribed with a novel agent, famitinib malate, and completed their follow - ups in center from October 2011 to June 2015. Details related to the adverse events and core managements were recorded. Re- suits Proteinuria, leukopenia, thrombocytopenia, hand foot syndrome, hypertension, anemia, anorexia, diarrhea, hematuria, edema and oral mucositis occurred in 88.9%, 88.9%, 88.9%, 77.8%, 66.7%, 66.7%, 66.7% ; 55, 6%, 33.3%, 22.2% and 22, 2% of the patients, respectively. With appropriate management of symptoms and timely modification of the doses as well as nursing care, all adverse events were controllable. Conclusion The adverse event rates were high in metastatic renal ceil cancer patients treated with famitinib malate. The active moni- tor of adverse events and nursing care ensure the safety and the ~reatest benefit during the theranv.